Similar to this, miR-200c improved NSCLC cells’ susceptibility to gefitinib by obstructing the PI3K/Akt signaling pathway (74).MiR-223 expression was significantly reduced in the TKI-resistant cell lines PC9/ER and PC9/CD133+ cells, and overexpression of miR-223 would attenuate the cellular expression of IGF1R mRNA and p-Akt levels, thus restoring the sensitivity of resistant cells to erlotinib (75). The gene discussed is PIK3CB; the disease is non-small cell lung carcinoma.